The Strongest Semaglutide Dose: What the Evidence Actually Shows

Step 1: why semaglutide starts low and builds slowly

Semaglutide for weight management begins at 0.25mg weekly. That first dose is not intended to produce significant weight loss; its job is to let your body adjust to the medicine before the dose climbs. The most common side effects (nausea, loose stools, reflux) are most likely to appear when the drug is first introduced or when the dose increases, so the gradual titration schedule exists to reduce the chance of those effects becoming intolerable.

From 0.25mg, the standard schedule moves through 0.5mg, 1.0mg and 1.7mg, with roughly four weeks at each level. Your prescriber may slow that pace if side effects are significant, or continue at the current dose for longer if that is the clinically appropriate call. Telling your prescribing team how you are feeling at each stage is what allows the titration to be personalised rather than mechanical.

The NHS patient information page for semaglutide summarises what to expect during the dose-escalation period, including which side effects are common and what warrants urgent attention. Reading it before starting is time well spent.

Step 2: what the 2.4mg maintenance dose delivers in practice

For most people, 2.4mg weekly has been the maintenance target since Wegovy's UK launch. The STEP 1 trial (published in the New England Journal of Medicine) followed adults with obesity over 68 weeks and recorded an average body-weight reduction of around 15% at 2.4mg alongside lifestyle changes. That is a meaningful shift; no oral medicine available in the UK at that time came close.

A question our prescribers hear most weeks is whether staying at a lower dose for longer produces the same result as reaching 2.4mg. The honest answer, based on the trial structure, is that higher doses drove greater average loss. That said, individual responses vary considerably; some people see strong results before reaching the maximum, others need the full dose before appetite suppression becomes consistent.

Practical context matters here too. If you are considering the cost of treatment at different dose levels, our Wegovy pricing page covers what a private prescription typically involves. The dose you are prescribed affects the pen you receive, so understanding the full picture before you start is sensible.

Step 3: the 7.2mg approval and what it adds

The MHRA approved a 7.2mg weekly maintenance dose for semaglutide in January 2026. A dedicated single-dose 7.2mg pen (one pre-set injection per week, with a built-in covered needle that locks after use) received approval on 14 April 2026. This higher dose is licensed for adults with a BMI of 30 or above for weight management; it is not approved for the cardiovascular indication at this strength.

Trial data at 7.2mg reported approximately 20.7% average weight loss over 72 weeks. That narrows the gap considerably with tirzepatide, which produced around 20 to 22% in SURMOUNT-1 at its 15mg ceiling. If you are trying to make sense of how semaglutide and tirzepatide compare head-to-head at their respective maximums, the semaglutide treatment overview sets out the key distinctions, and the question of what is stronger than semaglutide is covered in full on a dedicated page.

The 7.2mg dose is not a starting point. Patients begin at 0.25mg regardless of whether they ultimately reach 7.2mg. Specific dose and pen availability is confirmed at consultation, because dispensing decisions depend on clinical assessment and current stock at the time of prescribing. Never assume a particular pen format is automatically available.

Step 4: who the highest dose is, and is not, suitable for

Semaglutide at any strength is a prescription-only medicine, and the decision to increase to 7.2mg sits with the prescriber, not the patient. Dose increases are appropriate only when the previous level has been tolerated and the clinical picture supports going higher. People who experience persistent, significant nausea, vomiting or other side effects may be held at a lower dose for longer — or may find that a lower dose is their effective maintenance point.

The licensed population for Wegovy is adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as hypertension, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The medicine is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. It is not licensed for under-18s.

Anyone on oral contraceptives taking tirzepatide (not semaglutide) should note separate guidance about absorption of the pill during dose increases; the Wegovy page covers what is specific to semaglutide on this point. If you have had Covid and are wondering how that affects your treatment, the relationship between Covid and Wegovy is explained in full on a dedicated page. You can also explore how Wegovy compares to older weight-loss injections if you want a broader picture before deciding to proceed. Our weight-loss treatment overview summarises the options currently available through nume for anyone still weighing up which route suits them.